OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
June 24, 2022
GSK will invest £1 billion in furthering R&D in malaria, tuberculosis, and HIV, as well as neglected tropical diseases.
June 21, 2022
Avid Bioservices has expanded its viral vector development and manufacturing facility with the addition of analytical and process development suites.
Orbit Discovery has been awarded the Innovate UK Grant to expand high throughput cell-based functional screening platform capabilities in peptide drug discovery.
June 17, 2022
A new polymer surface material has been invented by researchers in Sweden that uses electrical signals to both capture and release biomolecules.
June 13, 2022
Precision BioSciences has released clinical trial data on CAR T therapy candidates PBCAR0191, PBCAR19B, and PBCAR269A.
June 03, 2022
Thermo Fisher Scientific and Qatar Genome Program will use custom genotyping arrays to accelerate genomic research in Qatar.
Putting the patient at the forefront of drug development is essential, particularly to ensure medication compliance is optimized.
The right processes used with the right excipient combinations address evolving formulation needs.
Collecting relevant data, planning ahead, and communicating with regulatory bodies in pre-IND meeting programs can help companies to avoid roadblocks in IND applications.
June 02, 2022
The inaugural Connect in Pharma event will take place on 14 and 15 September in Geneva, Switzerland.